Table 1.

Clinical and demographic characteristics of patients treated on ALL protocols, 2012–2017

OverallMTX neurotoxicity
(n = 280)Yes (n = 39)No (n = 241)P
Age at diagnosis, mean (SD)8.40 (4.36)12.20 (3.27)7.79 (4.21)<0.01
BMI Z-score, mean (SD)0.23 (1.31)0.80 (1.20)0.14 (1.31)<0.01
Patient sex, n (%)0.99
 Male146 (52.1)20 (51.3)126 (52.3)
 Female134 (47.9)19 (48.7)115 (47.7)
Race/ethnicity, n (%)<0.01
 Non-Hispanic white100 (36.2)8 (20.5)92 (38.8)
 Hispanic133 (48.2)29 (74.4)104 (43.9)
 Non-Hispanic black23 (8.3)2 (5.1)21 (8.9)
 Non-Hispanic other20 (7.3)0 (0.0)20 (8.4)
Diagnosis, n (%)0.28
 B-ALL240 (85.7)31 (79.5)209 (86.7)
 T-ALL30 (10.7)7 (18.0)23 (9.5)
 Lymphoblastic lymphoma10 (3.6)1 (2.5)9 (3.7)
Treatment arm, n (%)<0.01
 Low/standard risk115 (41.5)6 (15.4)109 (45.8)
 High/very high risk162 (58.5)33 (84.6)129 (54.2)
Triple IT therapy, n (%)0.99
 None248 (89.9)34 (89.5)214 (89.9)
 Any28 (10.1)4 (10.5)24 (10.1)
Day 29 MRD, n (%)0.11
 <0.01%200 (74.1)24 (63.2)176 (75.9)
 ≥0.01%70 (25.9)14 (36.8)56 (24.1)
  • NOTE: P value from t test for continuous variable or Fisher exact test for categorical variables.

  • Abbreviations: IT, intrathecal; MTX, methotrexate; T-ALL, T-cell acute lymphoblastic leukemia.